Trump Signals Two Final Candidates for Fed Chair, Calls for Presidential Input on Interest Rates 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Global Leaders Condemn Deadly Antisemitic Shooting at Sydney’s Bondi Beach During Hanukkah 
Hong Kong Democratic Party Disbands After Member Vote Amid Security Crackdown 
Preservation Group Sues Trump Administration to Halt $300 Million White House Ballroom Project 
New Epstein Photos Surface Showing Trump as Lawmakers Near Document Release Deadline 
Nvidia Develops New Location-Verification Technology for AI Chips 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Belarus Pledges to Halt Smuggling Balloons Into Lithuania 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
U.S. Soldiers Killed in ISIS Attack in Palmyra, Syria During Counterterrorism Mission 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Zelenskiy Signals Willingness to Drop NATO Bid as Ukraine, U.S. Hold Crucial Peace Talks in Berlin 
President Donald Trump has announced a new agreement with UK-based pharmaceutical giant AstraZeneca, following a similar deal with Pfizer, aimed at cutting prescription drug prices in the United States. Under the pact, AstraZeneca will provide certain medicines to the U.S. Medicaid health program at discounted rates in exchange for relief from import tariffs, marking another step in the administration’s push to lower healthcare costs.
The deal forms part of the White House’s broader strategy to pressure major drugmakers to align U.S. prices with those in other developed nations, where patients often pay nearly three times less. In July, Trump sent letters to 17 leading pharmaceutical companies urging them to reduce prices or face steep tariffs. AstraZeneca and Pfizer are the first to comply, setting the stage for future negotiations.
AstraZeneca CEO Pascal Soriot revealed that the company will offer select drugs at up to 80% off their list prices through the upcoming TrumpRx online platform. In return, the firm will receive a three-year tariff exemption to support its plan to localize more of its production in the U.S. Soriot emphasized AstraZeneca’s growing American footprint, noting a $50 billion investment in U.S. manufacturing and R&D by 2030, including a massive new site in Virginia.
While the initiative may ease costs for Medicaid, experts remain skeptical about its broader impact. Northwestern University professor Craig Garthwaite noted that Medicaid already benefits from the nation’s lowest drug prices, suggesting limited savings. Boston University’s Rena Conti added that while the agreement benefits pharmaceutical firms, it offers little relief to Americans struggling with high out-of-pocket costs.
AstraZeneca’s latest moves reflect its effort to strengthen ties with Washington while expanding U.S. operations, including plans to list its shares on U.S. markets and sell some drugs directly to cash-paying patients at significant discounts.
